These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23831869)

  • 21. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influences of CYP2D6
    Pei Q; Huang L; Huang J; Gu JK; Kuang Y; Zuo XC; Ding JJ; Tan HY; Guo CX; Liu SK; Yang GP
    Acta Pharmacol Sin; 2016 Nov; 37(11):1499-1508. PubMed ID: 27665849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
    Dorado P; Peñas-Lledó EM; Llerena A
    Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6.
    Dettling M; Sachse C; Müller-Oerlinghausen B; Roots I; Brockmöller J; Rolfs A; Cascorbi I
    Pharmacopsychiatry; 2000 Nov; 33(6):218-20. PubMed ID: 11147929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
    Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
    Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.
    Dorado P; Berecz R; Peñas-Lledó EM; Cáceres MC; Llerena A
    Curr Drug Targets; 2006 Dec; 7(12):1671-80. PubMed ID: 17168842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine.
    Jaquenoud Sirot E; Knezevic B; Morena GP; Harenberg S; Oneda B; Crettol S; Ansermot N; Baumann P; Eap CB
    J Clin Psychopharmacol; 2009 Aug; 29(4):319-26. PubMed ID: 19593168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.
    Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA
    Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytochrome P450 polymorphisms and response to antipsychotic therapy.
    Scordo MG; Spina E
    Pharmacogenomics; 2002 Mar; 3(2):201-18. PubMed ID: 11972442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses.
    Fleeman N; Dundar Y; Dickson R; Jorgensen A; Pushpakom S; McLeod C; Pirmohamed M; Walley T
    Pharmacogenomics J; 2011 Feb; 11(1):1-14. PubMed ID: 20877299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
    Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
    Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
    Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2D6 mutations and therapeutic outcome in schizophrenic patients.
    Hamelin BA; Dorson PG; Pabis D; Still D; Bouchard RH; Pourcher E; Rail J; Turgeon J; Crismon ML
    Pharmacotherapy; 1999 Sep; 19(9):1057-63. PubMed ID: 10610012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
    Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
    Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.
    Mas S; Gassó P; Torra M; Bioque M; Lobo A; González-Pinto A; Olmeda MS; Corripio I; Vieta E; Castro-Fornieles J; Rodriguez-Jimenez R; Bobes J; Usall J; Llerena A; Saiz-Ruiz J; Bernardo M; Lafuente A; PEPs Group
    Eur Neuropsychopharmacol; 2017 Jul; 27(7):647-656. PubMed ID: 28389049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.
    Jameson A; Faisal M; Fylan B; Bristow GC; Sohal J; Dalton C; Sagoo GS; Cardno AG; McLean SL
    J Psychopharmacol; 2024 Apr; 38(4):382-394. PubMed ID: 38494658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
    Bork JA; Rogers T; Wedlund PJ; de Leon J
    J Clin Psychiatry; 1999 Jul; 60(7):469-76. PubMed ID: 10453802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.
    Barteček R; Juřica J; Zrůstová J; Kašpárek T; Pindurová E; Žourková A
    Neuro Endocrinol Lett; 2012; 33(2):236-44. PubMed ID: 22592207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.
    Jürgens G; Andersen SE; Rasmussen HB; Werge T; Jensen HD; Kaas-Hansen BS; Nordentoft M
    JAMA Netw Open; 2020 Dec; 3(12):e2027909. PubMed ID: 33284338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.